Provectus Biopharmaceuticals Launches VisiRose, Provectus’s Founded Entity for Pharmaceutical-grade Rose Bengal Sodium-based Treatments in Ophthalmology
11. Dezember 2024 09:00 ET
|
Provectus Biopharmaceuticals Inc.
KNOXVILLE, Tenn., Dec. 11, 2024 (GLOBE NEWSWIRE) -- Provectus Biopharmaceuticals, Inc. (“Provectus” or the “Company”) (OTCQB: PVCT) announced today the launch of VisiRose, Inc. (“VisiRose”),...
Provectus Biopharmaceuticals Announces Fourth Quarter 2024 Conference Call
10. Oktober 2024 08:00 ET
|
Provectus Biopharmaceuticals Inc.
KNOXVILLE, Tenn., Oct. 10, 2024 (GLOBE NEWSWIRE) -- Provectus Biopharmaceuticals, Inc. (“Provectus” or the “Company”) (OTCQB: PVCT) announced today that it will host a conference call on Thursday,...
Provectus Biopharmaceuticals Announces Publication of Australian Compassionate Use Patients Treated with PV-10® Immunotherapy for In-Transit Melanoma Lesions
31. März 2021 07:00 ET
|
Provectus Biopharmaceuticals Inc.
46% complete response of patients at Melanoma Institute AustraliaFifth published study of in-transit melanoma lesion treatment with single-agent PV-1026-50% complete response (52-86% overall response)...
Provectus Biopharmaceuticals Receives Notice of Allowance for Adult Solid Tumor Cancer Combination Therapy Patent for PV-10® Immunotherapy from United States Patent and Trademark Office
30. März 2021 07:00 ET
|
Provectus Biopharmaceuticals Inc.
KNOXVILLE, TN, March 30, 2021 (GLOBE NEWSWIRE) -- Provectus (OTCQB: PVCT) today announced that the United States Patent and Trademark Office (USPTO) has allowed US patent (USP) application...
Provectus Biopharmaceuticals Announces Oral Presentation of Updated Data from Combination Therapy Trial of PV-10® and Keytruda® for Checkpoint-Refractory Advanced Cutaneous Melanoma at Melanoma Bridge 2020
07. Dezember 2020 07:00 ET
|
Provectus Biopharmaceuticals Inc.
29% ORR (7% CR) and 57% DCR (RECIST 1.1)75% ORR in anti-PD-1-refractory patients56% DCR (11% CR) in patients refractory to anti-CTLA-4 and anti-PD-1 combination therapyPresentation delivered by...
Provectus Biopharmaceuticals Announces Acceptance of PV-10® Pancreatic Cancer Abstract at 2020 Society for Immunotherapy of Cancer (SITC) Annual Meeting
15. Oktober 2020 08:00 ET
|
Provectus Biopharmaceuticals Inc.
KNOXVILLE, TN, Oct. 15, 2020 (GLOBE NEWSWIRE) -- Provectus (OTCQB: PVCT) today announced that H. Lee Moffitt Cancer Center will present non-clinical data from ongoing research on investigational...
Provectus Biopharmceuticals Highlights Stage IV M1d Patient Outcome from Combination Therapy Trial of PV-10® and KEYTRUDA® for Checkpoint-Refractory Advanced Cutaneous Melanoma at ESMO Virtual Congress 2020
21. September 2020 14:05 ET
|
Provectus Biopharmaceuticals Inc.
Complete response of all injected lesionsRegression of non-injected inguinal node, lung, and brain metastasesExpanded data set of trial subject provided KNOXVILLE, TN, Sept. 21, 2020 (GLOBE...
Provectus Biopharmaceuticals Establishes Research Collaboration with University of Tennessee Health Science Center to Investigate Small Molecule Rose Bengal Disodium for Antibiotic Resistance
09. September 2020 08:00 ET
|
Provectus Biopharmaceuticals Inc.
KNOXVILLE, TN, Sept. 09, 2020 (GLOBE NEWSWIRE) -- Provectus (OTCQB: PVCT) today announced that the Company has initiated a new sponsored research program with Michio Kurosu, PhD, Professor,...
Provectus Biopharmaceuticals Expands Global Patent Portfolio to India for Cancer Combination Therapy
09. Juni 2020 09:00 ET
|
Provectus Biopharmaceuticals Inc.
2020 India patent follows 2018 India patent that protects Provectus’ proprietary API manufacturing processProvectus further expands cancer combination therapy IP protection by filing new USPTO patent...
Provectus Announces Acceptance of PV-10® Liver Cancer Abstracts at American Society of Clinical Oncology (ASCO) 2020 Virtual Scientific Program
29. April 2020 16:30 ET
|
Provectus Biopharmaceuticals Inc.
KNOXVILLE, TN, April 29, 2020 (GLOBE NEWSWIRE) -- Provectus (OTCQB: PVCT) today is pleased to announce that abstracts about and data from our clinical trials of investigational autolytic cancer...